These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 19222899)

  • 1. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation.
    Elder DP; Snodin DJ
    J Pharm Pharmacol; 2009 Mar; 61(3):269-78. PubMed ID: 19222899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The utility of sulfonate salts in drug development.
    Elder DP; Delaney E; Teasdale A; Eyley S; Reif VD; Jacq K; Facchine KL; Oestrich RS; Sandra P; David F
    J Pharm Sci; 2010 Jul; 99(7):2948-61. PubMed ID: 20112423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Residues of genotoxic alkyl mesylates in mesylate salt drug substances: real or imaginary problems?
    Snodin DJ
    Regul Toxicol Pharmacol; 2006 Jun; 45(1):79-90. PubMed ID: 16564608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs).
    Elder DP; Teasdale A; Lipczynski AM
    J Pharm Biomed Anal; 2008 Jan; 46(1):1-8. PubMed ID: 18053672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
    Elder DP; Lipczynski AM; Teasdale A
    J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of genotoxic impurities in pharmaceutical development.
    Bercu JP; Dobo KL; Gocke E; McGovern TJ
    Int J Toxicol; 2009; 28(6):468-78. PubMed ID: 19966139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances.
    An J; Sun M; Bai L; Chen T; Liu DQ; Kord A
    J Pharm Biomed Anal; 2008 Nov; 48(3):1006-10. PubMed ID: 18687555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety assessment of xylene sulfonic acid, toluene sulfonic acid, and alkyl aryl sulfonate hydrotropes as used in cosmetics.
    Bergfeld WF; Belsito DV; Klaassen CD; Hill R; Liebler D; Marks JG; Shank RC; Slaga TJ; Snyder PW; Andersen FA
    Int J Toxicol; 2011 Dec; 30(6 Suppl):270S-83S. PubMed ID: 22247238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genotoxicity profiles of common alkyl halides and esters with alkylating activity.
    Sobol Z; Engel ME; Rubitski E; Ku WW; Aubrecht J; Schiestl RH
    Mutat Res; 2007 Oct; 633(2):80-94. PubMed ID: 17644026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The application of structure-based assessment to support safety and chemistry diligence to manage genotoxic impurities in active pharmaceutical ingredients during drug development.
    Dobo KL; Greene N; Cyr MO; Caron S; Ku WW
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):282-93. PubMed ID: 16464524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
    Müller L; Gocke E; Lavé T; Pfister T
    Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent developments in the risk assessment of potentially genotoxic impurities in pharmaceutical drug substances.
    Humfrey CD
    Toxicol Sci; 2007 Nov; 100(1):24-8. PubMed ID: 17656486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a sensitive method for alkyl sulfonate genotoxic impurities determination in drug substances using gas chromatography coupled to triple quadrupole mass spectrometry.
    Liu Z; Fan H; Zhou Y; Qian X; Tu J; Chen B; Duan G
    J Pharm Biomed Anal; 2019 May; 168():23-29. PubMed ID: 30784886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity.
    Müller L; Mauthe RJ; Riley CM; Andino MM; Antonis DD; Beels C; DeGeorge J; De Knaep AG; Ellison D; Fagerland JA; Frank R; Fritschel B; Galloway S; Harpur E; Humfrey CD; Jacks AS; Jagota N; Mackinnon J; Mohan G; Ness DK; O'Donovan MR; Smith MD; Vudathala G; Yotti L
    Regul Toxicol Pharmacol; 2006 Apr; 44(3):198-211. PubMed ID: 16412543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-clinical toxicological considerations for pharmaceutical salt selection.
    Thackaberry EA
    Expert Opin Drug Metab Toxicol; 2012 Nov; 8(11):1419-33. PubMed ID: 22950715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acid-mediated formation of trifluoromethyl sulfonates from sulfonic acids and a hypervalent iodine trifluoromethylating agent.
    Koller R; Huchet Q; Battaglia P; Welch JM; Togni A
    Chem Commun (Camb); 2009 Oct; (40):5993-5. PubMed ID: 19809621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Advances on genotoxic impurities of sulfonate esters in pharmaceuticals].
    Liu X; Li C; Han H; Zhang W; Chen D
    Se Pu; 2018 Oct; 36(10):952-961. PubMed ID: 30378353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eliminating pharmaceutical impurities: Recent advances in detection techniques.
    Liu DQ; Sun M; Wu L
    Curr Opin Drug Discov Devel; 2010; 13(6):748-57. PubMed ID: 21061235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Direct synthesis of sulfonamides and activated sulfonate esters from sulfonic acids.
    Caddick S; Wilden JD; Judd DB
    J Am Chem Soc; 2004 Feb; 126(4):1024-5. PubMed ID: 14746462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Viracept (nelfinavir)--ethyl methanesulfonate case: a threshold risk assessment for human exposure to a genotoxic drug contamination?
    Lutz WK
    Toxicol Lett; 2009 Nov; 190(3):239-42. PubMed ID: 19695319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.